

Substitute for form 1449A&B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/580,635	
				Filing Date	April 11, 2007	
				First Named Inventor	Pastan, Ira H.	
				Art Unit	1644	
Examiner Name	Crowder, Chun					
Attorney Docket Number	015280-500100US					
Sheet	1	of	2			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AA	WO	00/73346	A1	12-07-2000			<input type="checkbox"/>
	AB	WO	03/027135	A2	04-03-2003			<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AC	BANG, Sookhee et al.; "HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity and therapeutic index"; 2004, <u>Proceedings of the American Association for Cancer Research Annual Meeting</u> , Vol. 45, page 144.	<input type="checkbox"/>
	AD	BANG, Sookhee et al.; "HA22 (R490A) is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity"; 2005, <u>Clinical Cancer Research</u> Vol. 2, pp. 1545-1550.	<input type="checkbox"/>
	AE	BEERS, Richard et al.; "Immunotoxins with Increased Activity against Epidermal Growth Factor Receptor VIII-expressing Cells Produced by Antibody Phage display"; 2000, <u>Clinical Cancer Research</u> Vol. 6, pp. 2835-2843.	<input type="checkbox"/>
	AF	BRINKMANN, Ulrich et al.; "Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice"; 1992, <u>Proceedings of the National Academy of Science</u> , Vol. 89, pp. 3065-3069.	<input type="checkbox"/>
	AG	CHOWDHURY, Partha S. et al.; "Improving antibody affinity by mimicking somatic hypermutation in vitro"; 1999, <u>Nature Biotechnology</u> , Vol. 17, pp. 568-572.	<input type="checkbox"/>
	AH	DECKER, Thomas et al.; "Induction of Caspase-Dependent Programmed Cell Death in B-CLL Cells by Recombinant Anti-CD22 Immunotoxins"; 2003, <u>Blood</u> , Vol. 102, No. 11, page 439a.	<input type="checkbox"/>
	AI	HO, Mitchell et al.; "In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin"; 2005, <u>The Journal of Biological Chemistry</u> , Vol. 280, NO. 1, pp. 607-617.	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/580,635
				Filing Date	April 11, 2007
				First Named Inventor	Pastan, Ira H.
				Art Unit	1644
Examiner Name	Crowder, Chun				
Sheet	2	of	2	Attorney Docket Number	015280-500100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AJ	KREITMAN, Robert J.; "Chimeric fusion proteins - <i>Pseudomonas</i> exotoxin-based"; 2001, <u>Current Opinion in Investigational Drugs</u> , Vol 2, No. 9, pp. 1282-1293.	<input type="checkbox"/>
	AK	SALVATORE, Giuliana et al.; "Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display"; 2002, <u>Clinical Cancer Research</u> , Vol. 8, pp. 995-1002.	<input type="checkbox"/>
	AL	TSUTSUMI, Yasuo et al.; "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity"; 2000, <u>Proceedings of the National Academy of Science</u> , Vol. 97, No. 15, pp. 8548-8553.	<input type="checkbox"/>
	AM	YATES, Susan P. et al.; "A Catalytic Loop within <i>Pseudomonas aeruginosa</i> Exotoxin A Modulates Its Transferase Activity"; 2001, <u>The Journal of Biological Chemistry</u> , Vol. 276, No. 37, pp. 35029-35036.	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.